Tscan Therapeutics is expected to report a Q2 2026 loss of $0.29 per share on revenue of $1.88 million, with the stock currently trading at $0.80 against a consensus price target of $6.00. Investors are primarily focused on clinical pipeline progress, specifically the planned initiation of the Phase 3 ALLOHA-2 pivotal trial for lead candidate TSC-101.
Recent data from the Phase 1 ALLOHA study has shown high rates of complete donor chimerism, reinforcing optimism in the company’s TCR-T platform for heme malignancies. Management's updated guidance on its cash runway, currently projected to last into the second half of 2027, remains a critical secondary focus as manufacturing scaling efforts continue.